Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.69 |
| ▸ | CTSD | P07339 | 2/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913118 | 0.88 | BACE1 (0.71) | BACE1CTSDBACE2 | |
| SCHEMBL9913103 | 0.87 | BACE1 (0.67) | BACE1CTSDBACE2 | |
| SCHEMBL7922354 | 0.87 | BACE1 (0.67) | BACE1CTSDBACE2 | |
| SCHEMBL1936055 | 0.85 | BACE1 (0.50) | BACE1CTSDBACE2 | |
| SCHEMBL3301433 | 0.85 | BACE1 (0.50) | BACE1CTSDBACE2 | |
| SCHEMBL12558207 | 0.84 | BACE1 (0.76) | BACE1CTSDBACE2 | |
| SCHEMBL1935194 | 0.82 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL1935609 | 0.82 | BACE1 (0.47) | BACE1CTSDBACE2 | |
| SCHEMBL1935133 | 0.82 | BACE1 (0.47) | BACE1CTSDBACE2 | |
| SCHEMBL7924424 | 0.81 | BACE1 (0.66) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | claimed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | claimed |
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2332943-B1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2332943-B1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-8933221-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2332943-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| WO-2010038686-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | BACE1 1/4885CTSD 595/4885BACE2 2/4885 |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885CTSD 1910/4885BACE2 3/4885 |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | BACE1 3093/4885CTSD 2408/4885BACE2 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.